Scroll down


KeyGene invented a CRISPR-based technology, whereby gRNAs guide CAS to target regions of interest within the DNA. The gRNA-CAS complex cuts out the target region and sticks to the target to protect it from exonuclease degradation. At the same time, non-protected off-target DNA will be digested, so that the protected target regions increase in relative frequency and can be sequenced in an ‘enriched’ way.

Benefits of KeyGene’s targeted sequencing technology

The technology is highly flexible with regard to target sequence length (1-20 Kb) and the number of targets to be enriched. Moreover, the technology is PCR-free, and as such, is not biased by preferential amplification of for instance specific alleles.


In research and fields like crop breeding, there is a high demand for a technology that can enrich samples to be sequenced for target sequences in a cost-effective way without PCR bias. KeyGene’s technology for targeted sequencing is highly instrumental in elucidating complex genomic structures, like copy number variation, larger insertions, and deletions, and inversions, when linked to long-read sequencing.


Click on the link for an overview of the patent families in the European Patent Register: WO2020/109412

Please note that the European Patent Register may not be extensive and/or accurate, for which KeyGene is not responsible. Please contact your patent expert for further information.

Image on the right: an example of successful targeted sequencing, using KeyGene’s proprietary technology